Background Matrix metalloproteases (MMPs) have been implicated in the pathogenesis of acute myocardial infarction (AMI). However, little is known about the association between MMP-9 and myocardial no-reflow. The aim of this study was to evaluate the role of MMP-9 at the infarct-related artery as a predictor of no-reflow in patients with ST-elevation AMI.
Methods We prospectively enrolled 90 eligible ST-elevation AMI patients, undergoing successful primary PCI. Blood samples were obtained from the extraction catheter placed distal to the culprit lesion at the beginning of PCI. The levels of MMP-9 were determined in duplicate using the RayBio enzyme-linked immunosorbent assay.
Results No-reflow was observed in twenty-five patients (27.8%). Using multiple logistic regression analysis, local MMP-9 level (OR 3.356, CI: 1.441–16,881; p = 0.007) were found to be a significant risk factor of no-reflow together with lesion length (OR 6.985, CI: 1.574–18.533; p = 0.009) and thrombus score (OR 5.105, CI: 1.825–25.138; p = 0.041).
Conclusions Elevation of MMP-9 level in the culprit coronary artery may predict no-reflow in patients with ST-elevation AMI underwent PCI.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.